

Appendix 3Y

Change of Director's Interest Notice

Name of entity	Impression Healthcare Limited
ABN	93 096 635 246

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Sudhanshu AGARWAL
Date of last notice	7 January 2020

Part 1 - Change of director's relevant interests in securities

Direct or indirect interest	Indirect
Nature of indirect interest	Dr Agarwal is a shareholder, CEO and director of Cannvalate Pty Ltd ("Cannvalate"). Positions disclosed in this Appendix 3Y are held by Cannvalate. Dr Agarwal does not have sole discretion over the acquisition or disposal of these positions.
Date of change	13 February 2020
No. and class of securities held prior to change	<ul style="list-style-type: none"> 10,000,000 fully paid ordinary shares ("IHL") 10,000,000 \$0.03 unlisted options expiry 01-May-20 12,000,000 \$0.04 unlisted options expiry 01-May-20 14,000,000 \$0.06 unlisted options expiry 01-Dec-20 16,000,000 \$0.08 unlisted options expiry 01-Dec-20 18,000,000 \$0.10 unlisted options expiry 01-Dec-20 20,000,000 \$0.12 unlisted options expiry 01-Dec-20 20,000,000 \$0.14 unlisted options expiry 01-Dec-20
Number and class of securities acquired	10,000,000 ordinary fully paid shares
Number and class of securities disposed	10,000,000 \$0.03 unlisted options expiry 01-May-2020
Value/Consideration	\$300,000 (\$0.03 per option)
No. of securities held after change	<ul style="list-style-type: none"> 20,000,000 fully paid ordinary shares ("IHL") 12,000,000 \$0.04 unlisted options expiry 01-May-20 14,000,000 \$0.06 unlisted options expiry 01-Dec-20 16,000,000 \$0.08 unlisted options expiry 01-Dec-20 18,000,000 \$0.10 unlisted options expiry 01-Dec-20 20,000,000 \$0.12 unlisted options expiry 01-Dec-20 20,000,000 \$0.14 unlisted options expiry 01-Dec-20
Nature of change	Exercise of options

Part 2 – Change of director's interests in contracts – no change

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/a
If prior written clearance was provided, on what date was this provided?	N/a